Key facts
- It has raised $184.6M; the latest was Later Stage VC ($149.3M) in May 2025.
- Notable investors include Forbion, Schroders Capital, Pictet, Asahi Kasei Corporate Venture Capital, Asahi Kasei Pharma Venture Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Azafaros
- ·The full record, as it builds
Funding rounds
No funding rounds for Azafaros are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Azafaros
Developer of therapeutic agents designed for the treatment of rare metabolic disorders through oral administration of aza-sugar compounds. The company develops drugs that address lysosomal storage disorders and are designed to treat the central nervous system and interfere with the metabolism of glycosphingolipids, affecting key disease pathways through a unique dual mode of action, enabling healthcare providers to cure patients and improve their lives.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2018
- Employees
- 22
- Website
- azafaros.com/
- Ownership
- Privately Held (backing)
Azafaros doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Azafaros shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Azafaros in its N-PORT filings yet. We sweep new filings monthly.